Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 134Other solid neoplasm 2Breast 1

Conditions

Breast Neoplasms 10163Triple Negative Breast Neoplasms 1042Neoplasms 572Ovarian Neoplasms 560Neoplasm Metastasis 513Colorectal Neoplasms 467Carcinoma, Non-Small-Cell Lung 465Prostatic Neoplasms 439Lung Neoplasms 432Pancreatic Neoplasms 312Melanoma 299Stomach Neoplasms 294Breast Neoplasms, Male 257Motor Activity 252Colonic Neoplasms 238Uterine Cervical Neoplasms 225Endometrial Neoplasms 221Head and Neck Neoplasms 217Carcinoma, Intraductal, Noninfiltrating 217Carcinoma, Renal Cell 191Squamous Cell Carcinoma of Head and Neck 179Sarcoma 175Urinary Bladder Neoplasms 159Brain Neoplasms 155Esophageal Neoplasms 154Breast Carcinoma In Situ 154Lymphedema 148Fatigue 136Carcinoma, Ovarian Epithelial 134Small Cell Lung Carcinoma 128

Interventions

Pemetrexed 1Paclitaxel 1Drug Therapy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × NSCLC × Breast × Clear all
NCT06746870 2024-12-24

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 2 Not yet recruiting
148 enrolled
BreastThoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡